Unveiling Tigliane Derivatives as Novel Therapeutics for Alzheimer's Disease
Kausik Bhar1★, Sumanta Mondal2, Kazi Asraf Ali3, Saptarshi Samajdar1★ Corresponding author
- 1Department of Pharmaceutical Technology, Brainware University, Barasat, Kolkata, West Bengal, INDIA.
- 2Department of Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, INDIA.
- 3Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology, West Bengal, Nadia, West Bengal, INDIA.
CORRESPONDENCE
Kausik Bhar
Department of Pharmaceutical Technology, Brainware University, Barasat, Kolkata, West Bengal, INDIA.
Received: 14-07-2025; Revised: 03-09-2025; Accepted: 24-11-2025.
Volume 14, Issue 3 · pp. 532–540 · PUBLISHED · DOI: 10.5530/ajbls.20250029
ABSTRACT
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options. Current treatments offer only symptomatic relief without halting disease progression. Natural products and their derivatives have garnered increasing interest for neuroprotection. Among them, tigliane diterpenoids, primarily derived from the Euphorbiaceae family, have shown potent biological activities, including anti-inflammatory, antioxidant, and neuroprotective properties. This review examines the therapeutic potential of tigliane derivatives in the treatment of Alzheimer's disease, concentrating on their pharmacological effects, molecular mechanisms, and structure-activity relationships. Furthermore, we discuss challenges and prospects of tigliane-based drug development as novel interventions for AD.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Bhar, K., Mondal, S., Ali, K. A., & Samajdar, S. (). Unveiling Tigliane Derivatives as Novel Therapeutics for Alzheimer's Disease. Asian Journal of Biological and Life sciences, 14(3), 532–540. https://doi.org/10.5530/ajbls.20250029